Alte Antibiotika im neuen Glanz

Daniela Tominski; Juri Katchanov; Keikawus Arastéh; Hartmut Stocker

doi:10.1055/s-0033-1344753

Krankenhaushygiene up2date, Table of Contents

Krankenhaushygiene up2date 2013; 08(03): 185-198
DOI: 10.1055/s-0033-1344753

Antibiotikaanwendung

Alte Antibiotika im neuen Glanz

Wiederentdeckung älterer Antibiotika im Zeitalter der Problemkeime

Authors

Daniela Tominski
Juri Katchanov
Keikawus Arastéh
Hartmut Stocker

Abstract

All articles of this category

Full Text

References

Literatur
1 Bergen PJ, Landersdorfer CB, Lee HJ et al. „Old“ antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 2012; 25: 626-633
2 Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-1958
3 Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-260 ; 2nd page, table of contents
4 Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 2008; 6: 593-600
5 Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 2007; 13: 592-597
6 Farrell DJ, Castanheira M, Chopra I. Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis 52 Suppl 2011; 7: 487-492
7 Fernandes P, Pereira D. Efforts to support the development of fusidic acid in the United States. Clin Infect Dis 2011; 52: 542-546
8 Garonzik SM, Li J, Thamlikitkul V et al. Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically-Ill Patients from a Multi-Center Study Provide Dosing Suggestions for Various Categories of Patients. Antimicrob Agents Chemother 2011; 55: 3284-3294
9 Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-e120
10 IDSA. Bad Bugs, No Drugs. http://www.fda.gov/ohrms/dockets/dockets/04s0233/04s-0233-c000005-03-IDSA-vol1.pdf
11 Kashanian J, Hakimian P, Blute MJr et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int 2008; 102: 1634-1637
12 Kastoris AC, Rafailidis PI, Vouloumanou EK et al. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol 2010; 66: 359-368
13 Li J, Nation Rl, Owen Rj et al. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45: 594-598
14 Livermore D, James D, Duckworth G et al. Fusidic-acid use and resistance. Lancet 2002; 360: 806
15 Monden K, Ando E, Iida M et al. Role of fosfomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm. J Infect Chemother 2002; 8: 218-226
16 Nelson Ml, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci 2011; 1241: 17-32
17 Nickel JC. Management of urinary tract infections: historical perspective and current strategies: Part 2--Modern management. J Urol 2005; 173: 27-32
18 Nilsson AI, Berg OG, Aspevall O et al. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47: 2850-2858
19 Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-3436
20 Powers JH. Antimicrobial drug development--the past, the present, and the future. Clin Microbiol Infect 2004; 10 (Suppl. 04) 23-31
21 Rattanaumpawan P, Lorsutthitham J, Ungprasert P et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65: 2645-2649
22 Samonis G, Maraki S, Karageorgopoulos DE et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012; 31: 695-701
23 Schwartz RS. Paul Ehrlich’s magic bullets. N Engl J Med 2004; 350: 1079-1080
24 Shields Rk, Clancy Cj, Gillis Lm et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS 2012; One 7: e52349
25 Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999; 12 (Suppl. 02) 59-66
26 Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12 (Suppl. 02) 35-44
27 Velkov T, Thompson PE, Nation Rl et al. Structure--activity relationships of polymyxin antibiotics. J Med Chem 2010; 53: 1898-1916
28 Wolfe Cr. Case report: treatment of chronic osteomyelitis. Clin Infect Dis 2011; 52 (Suppl. 07) 538-541
29 Zaffiri L, Gardner J, Toledo-Pereyra LH. History of antibiotics. From salvarsan to cephalosporins. J Invest Surg 2012; 25: 67-77